mouse PD1重组蛋白作为抗原，用RPM1-14作为抗体，检测的EC50结合数据。

Mice were subcutaneously injected with MC38 (1 × 106) or B16-hCXCR4 (5 × 105). After two weeks, tumors bearing mice were intraperitoneally (ip) treated with murine anti-PD-1 [RMP1–14] (5 mg/kg, twice week for 2 weeks), Pep R (2 mg/kg, 5 days per week for 2 weeks), or both agents.The results indicate that the combined treatment, Pep R plus anti-PD-1, resulted in a 2.67-fold reduction in MC38 Relative Tumor Volume (RTV) (p = 0.038), while neither anti-PD-1 nor Pep R alone significantly affected tumor growth[2].